Supporting great science from around the world
The CARB-X portfolio is the world’s largest and most diverse portfolio of early development antibacterial projects. CARB-X provides non-dilutive funding and expertise to support the early development of antibiotics, vaccines, rapid diagnostics and other life-saving products. CARB-X supports therapeutics through the early development phases and Phase 1 so that they will attract additional private or public support for further clinical development. The CARB-X portfolio is focused on the greatest bacterial threats to human health, primarily those threats identified as “Urgent” and “Serious” in the 2019 CDC Threat Assessments or “Critical” or “High” in the 2017 Global Priority Pathogen List published by the WHO. Applications for funding are reviewed by the CARB-X Advisory Board and final funding decisions are made by the CARB-X Joint Oversight Committee.
The portfolio is constantly evolving, with new projects, advancements into clinical development, and achievement of milestones on the path to clinical trials. This gallery highlights product developers and projects that are currently in the CARB-X portfolio.